News for NervGen Pharma Corp. (NGENF)

Stifel has revised its price target for NervGen Pharma (NGENF), raising it from C$4.50 to C$5. The firm continues to maintain a Buy rating on the company's shar

NervGen Pharma (NGENF) has released encouraging topline results from its Phase 1b/2a clinical study of NVG-291, aimed at treating spinal cord injuries. The lead

NervGen Pharma's NVG-291 trial met a co-primary endpoint with significant improvement in hand muscle motor connectivity. 50% of patients on NVG-291 show

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical co

NervGen Pharma (OTCQB: NGENF) will present topline results from its NVG-291 chronic cohort Phase 1b/2a study at the 52nd American Spinal Injury Association

NervGen Pharma (NGENF) completed the last subject visit for its chronic cohort in the Phase 1b/2a trial, expecting data by early June 2025. The company

NervGen Pharma Corp. (NGENF) held its Annual General Meeting on May 6, 2025, where all proposed resolutions were successfully passed. Shareholders re-el

NervGen Pharma (OTCQB: NGENF) updated on their at-the-market (ATM) equity program for Q1 2025. The company sold 564,500 common shares at an average pric

Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

NervGen shares rated Market Perform

NervGen Pharma Corp. a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000...

NOTICE OF MEETING AND MANAGEMENT PROXY CIRCULAR FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS ...

Award Will Support 2nd Annual Spinal Cord Injury Investor Symposium To Be Held June 26 and 27, 2024 ...

NervGen Pharma Corp.  is pleased to announce the closing of its previously announced public offering including the full exercise of the underwriters' over-allotment option for aggregate gross...

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock...

A Vancouver biotech that is in early clinical trials with a drug that may repair damaged nerves in spinal cord injuries has received Food and Drug Administration (FDA) fast-track designation.

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that the U.S. Food and Drug...

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo,...